Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...